Singapore markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.29+1.49 (+7.16%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close20.80
Open21.00
Bid22.29 x 1000
Ask22.30 x 800
Day's range20.81 - 22.42
52-week range18.01 - 53.73
Volume897,839
Avg. volume683,739
Market cap628.402M
Beta (5Y monthly)1.17
PE ratio (TTM)N/A
EPS (TTM)-5.77
Earnings date04 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est51.64
  • Why Esperion Therapeutics Plummeted Nearly 22% Today
    Motley Fool

    Why Esperion Therapeutics Plummeted Nearly 22% Today

    Esperion Therapeutics (NASDAQ: ESPR) widely missed on its first-quarter results. In Q1 Esperion earned $8 million, over four times the $1.8 million of Q1 2020, fueled by $6.4 million in product revenue (royalty revenue came in at roughly $600,000).

  • Esperion (ESPR) Q1 Earnings Miss, Lower Drug Price Hits Sales
    Zacks

    Esperion (ESPR) Q1 Earnings Miss, Lower Drug Price Hits Sales

    Esperion Therapeutics (ESPR) reports dismal first-quarter results as it misses estimates for earnings and sales. Stock down.

  • Esperion Therapeutics Inc (ESPR) Q1 2021 Earnings Call Transcript
    Motley Fool

    Esperion Therapeutics Inc (ESPR) Q1 2021 Earnings Call Transcript

    With me on today's call are Tim Mayleben, President and Chief Executive Officer; Sheldon Koenig, Chief Operating Officer; and Rick Bartram, Chief Financial Officer. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the business.